Back to Search Start Over

The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium

Authors :
Dimitrios Poulimeneas
Markela Koniordou
Dimitra Kousi
Christina Merakou
Ioannis Kopsidas
Grammatiki Christina Tsopela
Christos D. Argyropoulos
Sophia C. Themistocleous
George Shiamakkides
Marinos Constantinou
Alexandra Alexandrou
Evgenia Noula
Andria Nearchou
Jon Salmanton-García
Fiona A. Stewart
Sarah Heringer
Kerstin Albus
Elena Álvarez-Barco
Alan Macken
Romina Di Marzo
Catarina Luis
Paula Valle-Simón
Helena H. Askling
Margot Hellemans
Orly Spivak
Ruth Joanna Davis
Anna Maria Azzini
Imre Barta
Lenka Součková
Ligita Jancoriene
Murat Akova
Patrick W. G. Mallon
Ole F. Olesen
Jesus Frias-Iniesta
Pierre van Damme
Krisztina Tóth
Miriam Cohen-Kandli
Rebecca Jane Cox
Petr Husa
Pontus Nauclér
Laura Marques
Jordi Ochando
Evelina Tacconelli
Markus Zeitlinger
Oliver A. Cornely
Zoi Dorothea Pana
Theoklis E. Zaoutis
Source :
Vaccines, Vol 11, Iss 12, p 1784 (2023)
Publication Year :
2023
Publisher :
MDPI AG, 2023.

Abstract

Underserved and hard-to-reach population groups are under-represented in vaccine trials. Thus, we aimed to identify the challenges of vaccine trial participation of these groups in member countries of the VACCELERATE network. Seventeen National Coordinators (NC), each representing their respective country (15 European countries, Israel, and Turkey), completed an online survey. From 15 eligible groups, those that were more frequently declared underserved/hard-to-reach in vaccine research were ethnic minorities (76.5%), persons experiencing homelessness (70.6%), illegal workers and refugees (64.7%, each). When prioritization for education on vaccine trials was considered, ethnic groups, migrants, and immigrants (5/17, 29.4%) were the groups most frequently identified by the NC as top targets. The most prominent barriers in vaccine trial participation affecting all groups were low levels of health literacy, reluctance to participate in trials due to engagement level, and low levels of trust in vaccines/vaccinations. This study highlighted population groups considered underserved/hard-to-reach in countries contained within the European region, and the respective barriers these groups face when participating in clinical studies. Our findings aid with the design of tailored interventions (within—and across—countries of the European region) and with the development of strategies to overcome major barriers in phase 2 and phase 3 vaccine trial participation.

Details

Language :
English
ISSN :
2076393X
Volume :
11
Issue :
12
Database :
Directory of Open Access Journals
Journal :
Vaccines
Publication Type :
Academic Journal
Accession number :
edsdoj.10e91baccf94e9faa5c72265d0677bc
Document Type :
article
Full Text :
https://doi.org/10.3390/vaccines11121784